Date of Graduation

12-2013

Document Type

Thesis (MS)

Program Affiliation

Biomedical Sciences

Degree Name

Masters of Science (MS)

Advisor/Committee Chair

Jonathan M. Kurie

Committee Member

Faye M. Johnson

Committee Member

Gregory Lizee

Committee Member

Vassiliki Papadimitrakopoulou

Committee Member

Ignacio I. Wistuba

Abstract

CXC chemokine receptor 2 (CXCR2) is a G-protein coupled receptor which mediates signaling by binding to CXC chemokines CXCL1-3 and 5-8. In non-small cell lung cancer CXCR2 has been studied mainly in stromal cells and is known to increase tumor inflammation and angiogenesis. However, there is controversial data in the literature about CXCR2 expression in tumor cells and its role in the tumor microenvironment. We hypothesized that tumoral expression of CXCR2 and its ligands promote tumor invasion and metastasis in non-small cell lung cancer. The effect of CXCR2 expression on tumor cells was studied using stable knockdown clones derived from a murine KRAS/p53–mutant lung adenocarcinoma cell line (344SQ) with high metastatic potential and an orthotopic syngeneic mouse model and in vitro using a CXCR2 small molecule antagonist (SB225002). We showed that in vivo CXCR2 inhibition by knock-down reduces its invasive ability. In a murine model of orthotopic syngeneic lung adenocarcinoma CXCR2 knock-down 344SQ cell line was found to be associated with decreased tumor burden, local and distant metastases. In order to translate our preclinical discoveries to human NSCLC, we explored CXCR2 tumoral immunohistochemical expression in 262 tissue microarrays created from tumor specimens of patients with surgically resected stage I-II lung adenocarcinoma and correlated it with patient clinic-pathological characteristics including smoking status, histological differentiation and survival outcomes. We considered also localization of CXCR2 expression in the cytoplasm, membrane and nucleus. High cytoplasmic CXCR2 was associated with smoking history, aggressive histological differentiation and worse survival. When we screened a publicly available large database of human NSCLC cell lines (N=52) and human lung adenocarcinomas (N=442), we found that at the gene expression level, CXCL5, a CXCR2-ligand, was the main driver of a cluster of cell lines and lung adenocarcinomas with high-risk features, including RAS and MET pathway activation, epithelial-to-mesenchimal transition and resistance to epidermal growth factor inhibition (i.e., gefitinib). We studied promoter methylation in 70 human non-small cell lung cancer cell lines and discovered that CXCL5 was regulated by promoter methylation. We concluded that the CXCR2 axis may be an important target in smoking-related lung adenocarcinoma.

Keywords

Lung adenocarcinoma, CXCR2, CXCL5, NSCLC, lung cancer metastases, CXCR2 ligands

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.